


Supplemental Figure S2. Plots showing percentage changes in total cfDNA concentration for each patient at weeks 4 and 8 of treatment, compared to same-patient baseline value. The left plot includes non-responding patients and the right plot includes patients who responded to olaparib in the clinical trial. Below, Mann-Whitney test comparing these changes at each time point for responders and non-responder patients.



	BASELINE cfDNA [ng/ml]			WEEK 4 % CHANGE FROM BASELINE			WEEK 8 % CHANGE FROM BASELINE		
	N	Median (IQR)	p-value	N	Median (IQR)	p-value	N	Median (IQR)	p-value
Overall	46	31.6 (19.4, 57.1)	p=0.29	46	-38.1% (-62.6, -4.5)	p=0.07	42	-28.8% (-55.1, +29.7)	p=0.006
Responders	16	42.0 (24.3, 57.9)		16	-51.4% (-72.6, -29.5)		16	-49.6% (-76.5, -20.3)	
Non-responders	30	30.2 (16.1, 57.1)		30	-33.4% (-52.3, +5.5)		26	+2.1% (-43.6, +57.8)	